Literature DB >> 23378183

Presence of antiphospholipid antibody is a risk factor in thrombotic events in patients with antiphospholipid syndrome or relevant diseases.

Koji Habe1, Hideo Wada, Takeshi Matsumoto, Kohshi Ohishi, Makoto Ikejiri, Kimiko Matsubara, Tatsuhiko Morioka, Yuki Kamimoto, Tomoaki Ikeda, Naoyuki Katayama, Tsutomu Nobori, Hitoshi Mizutani.   

Abstract

Antiphospholipid antibodies (aPL) including lupus anticoagulant (LA), anticardiolipin antibodies (aCL) IgG and aCL-β2-glycoprotein I (β2GPI) complex IG are causative factors for thrombotic event (THE). We retrospectively investigated relationships between aPLs and THE in 458 patients suspected of having antiphospholipid syndrome. THEs were observed in 232 of 458 patients, including 148 cases of venous thrombosis, 59 of arterial thrombosis, 18 of microthrombosis, and 20 of complications of pregnancy. The frequency of THE was significantly high in patients positive for LA and/or aPL. In patients with autoimmune disease (AID), the frequency of THE was significantly high in patients with any types of aPLs. Additionally, risk of THE was significantly increased in patients with more than two types of aPLs. Prolonged activated partial thromboplastin time indicated a high risk for THE. However, neither thrombocytopenia nor AID was a risk for THE. In conclusion, the presence of aPL is an indicator for high risk of THE in patients in whom THE was suspected. However, the risk of THE in aPL-positive patients varied among patients with different underlying diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23378183     DOI: 10.1007/s12185-013-1277-0

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  27 in total

1.  Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.

Authors:  F B Taylor; C H Toh; W K Hoots; H Wada; M Levi
Journal:  Thromb Haemost       Date:  2001-11       Impact factor: 5.249

Review 2.  Antiphospholipid syndrome: laboratory testing and diagnostic strategies.

Authors:  Thomas L Ortel
Journal:  Am J Hematol       Date:  2012-03-31       Impact factor: 10.047

3.  Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA).

Authors:  V Pengo; G Denas; E Bison; A Banzato; S Padayattil Jose; P Gresele; F Marongiu; N Erba; F Veschi; A Ghirarduzzi; E De Candia; B Montaruli; M Marietta; S Testa; D Barcellona; A Tripodi
Journal:  Thromb Res       Date:  2010-06-09       Impact factor: 3.944

Review 4.  ADAMTS-13 assays in thrombotic thrombocytopenic purpura.

Authors:  F Peyvandi; R Palla; L A Lotta; I Mackie; M A Scully; S J Machin
Journal:  J Thromb Haemost       Date:  2010-01-21       Impact factor: 5.824

Review 5.  APS--controversies in diagnosis and management, critical overview of current guidelines.

Authors:  Vittorio Pengo
Journal:  Thromb Res       Date:  2011-02       Impact factor: 3.944

Review 6.  Complement activation on platelets: implications for vascular inflammation and thrombosis.

Authors:  Ellinor I Peerschke; Wei Yin; Berhane Ghebrehiwet
Journal:  Mol Immunol       Date:  2010-06-01       Impact factor: 4.407

7.  Clinical study and follow-up of 100 patients with the antiphospholipid syndrome.

Authors:  F J Muñoz-Rodriguez; J Font; R Cervera; J C Reverter; D Tàssies; G Espinosa; A López-Soto; F Carmona; J Balasch; A Ordinas; M Ingelmo
Journal:  Semin Arthritis Rheum       Date:  1999-12       Impact factor: 5.532

Review 8.  Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis.

Authors:  T Atsumi; S Furukawa; O Amengual; T Koike
Journal:  Lupus       Date:  2005       Impact factor: 2.911

9.  Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome.

Authors:  Y Fujieda; T Atsumi; O Amengual; T Odani; K Otomo; M Kato; K Oku; Y Kon; T Horita; S Yasuda; T Koike
Journal:  Lupus       Date:  2012-08-30       Impact factor: 2.911

Review 10.  Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome.

Authors:  Henrique Luiz Staub; Maria Laura Bertolaccini; Munther A Khamashta
Journal:  Autoimmun Rev       Date:  2012-07-13       Impact factor: 9.754

View more
  3 in total

1.  Pro‑atherogenic activation of A7r5 cells induced by the oxLDL/β2GPI/anti‑β2GPI complex.

Authors:  Ting Wang; Hang Ouyang; Hong Zhou; Longfei Xia; Xiaoyan Wang; Ting Wang
Journal:  Int J Mol Med       Date:  2018-08-02       Impact factor: 4.101

Review 2.  Advances in the Research on Anticardiolipin Antibody.

Authors:  Dan Wang; Wenxin Lv; Shichang Zhang; Jiexin Zhang
Journal:  J Immunol Res       Date:  2019-12-01       Impact factor: 4.818

Review 3.  Thrombosis associated with mycoplasma pneumoniae infection (Review).

Authors:  Jingwei Liu; Yumei Li
Journal:  Exp Ther Med       Date:  2021-07-07       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.